CNChaoqun Nie

Chaoqun Nie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaoqun Nie has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Haoyu Wang

    Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China

    3 shared publications
  • Rong A

    Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Heilongjiang Province, China

    3 shared publications
  • Jing Wang

    Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China

    2 shared publications
  • Kaiqi Wang

    Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Harbin, China

    2 shared publications
  • Meifang Zhou

    Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, Heilongjiang Province, China

    2 shared publications
  • Rentong Zou

    Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

    2 shared publications

Latest Publications

  • Open Access

    Respiratory delivery of single low-dose nebulized PFCE-C25 NEs for lymphatic transport and durable stimulation of antitumor immunity in lung cancer

    by Rong A, Zhaoguo Han, Meifang Zhou, Chaoqun Nie, Mengyuan Zhu, Sijie Cheng, Tianyi Wang, Jing Wang, Zhen Quan, Kaiqi Wang, et al.

    The currently available immune checkpoint inhibitors (ICIs) often fail to achieve the desired clinical outcomes due to inadequate immune activation, particularly in patients with lung cancer. To reverse this situation, we synthesized inhalable PFCE-C25 nanoemulsions (NEs), which target lymphocyte activation genes (LAG-3) on immune cells within tumor microenvironment and tumor-draining lymph nodes (TDLNs). By combining in vivo 19 F-MR molecular imaging, we investigate the immunological effects of a single low-dose PFCE-C25 NEs in multiple murine lung cancer models, including human immune system (HIS) mouse models, and validated its immunological effects in human TDLNs. The nebulization therapy with PFCE-C25 NEs demonstrated a notable and enduring maturation of dendritic cells (DCs) in TDLNs, leading to systemic immune responses, prolonged survival, the establishment of immune memory, and resistance to tumor rechallenge. Thus, PFCE-C25 NEs successfully demonstrate a promising and efficient approach for enhancing lymphatic transport and sustained activation of antitumor immune responses in lung cancer.


  • Open Access

    Glycerol-weighted chemical exchange saturation transfer nanoprobes allow 19F/1H dual-modality magnetic resonance imaging-guided cancer radiotherapy

    by Rong A, Haoyu Wang, Chaoqun Nie, Zhaoguo Han, Meifang Zhou, Olagbaju Oluwatosin Atinuke, Kaiqi Wang, Xiance Wang, Shuang Liu, Jingshi Zhao, et al.

    Recently, radiotherapy (RT) has entered a new realm of precision cancer therapy with the introduction of magnetic resonance (MR) imaging guided radiotherapy systems into the clinic. Nonetheless, identifying an optimized radiotherapy time window (ORTW) is still critical for the best therapeutic efficacy of RT. Here we describe pH and O2 dual-sensitive, perfluorooctylbromide (PFOB)-based and glycerol-weighted chemical exchange saturation transfer (CEST) nano-molecular imaging probes (Gly-PFOBs) with dual fluorine and hydrogen proton based CEST MR imaging properties (19F/1H-CEST). Oxygenated Gly-PFOBs ameliorate tumor hypoxia and improve O2-dependent radiotherapy. Moreover, the pH and O2 dual-sensitive properties of Gly-PFOBs could be quantitatively, spatially, and temporally monitored by 19F/1H-CEST imaging to optimize ORTW. In this study, we describe the CEST signal characteristics exhibited by the glycerol components of Gly-PFOBs. The pH and O2 dual-sensitive Gly-PFOBs with19F/1H-CEST MR dual-modality imaging properties, with superior therapeutic efficacy and biosafety, are employed for sensitive imaging-guided lung cancer RT, illustrating the potential of multi-functional imaging to noninvasively monitor and enhance RT-integrated effectiveness.


  • Open Access

    Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting 19F MRI‐Guided Reperfusion Injury Therapy

    by Chaoqun Nie, Rong A, Jing Wang, Shuang Pan, Rentong Zou, Bin Wang, Shuiqing Xi, Xiaojian Hong, Meifang Zhou, Haoyu Wang, et al.

    Hydrogen gas is recently proven to have anti‐oxidative and anti‐inflammation effects on ischemia‐reperfusion injury. However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release. In this study, H2‐PFOB nanoemulsions (NEs) is developed with high hydrogen loading capacity for targeted ischemic myocardium precision therapy. The hydrogen‐carrying capacity of H2‐PFOB NEs is determined by gas chromatography and microelectrode methods. Positive uptake of H2‐PFOB NEs in ischemia‐reperfusion myocardium and the influence of hydrogen on 19F‐MR signal are quantitatively visualized using a 9.4T MR imaging system. The biological therapeutic effects of H2‐PFOB NEs are examined on a myocardial ischemia‐reperfusion injury mouse model. The results illustrated that the developed H2‐PFOB NEs can efficaciously achieve specific infiltration into ischemic myocardium and exhibit excellent antioxidant and anti‐inflammatory properties on myocardial ischemia‐reperfusion injury, which can be dynamically visualized by 19F‐MR imaging system. Moreover, hydrogen burst release induced by low‐intensity focused ultrasound (LIFU) irradiation further promotes the therapeutic effect of H2‐PFOB NEs with a favorable biosafety profile. In this study, the potential therapeutic effects of H2‐PFOB NEs is fully unfolded, which may hold great potential for future hydrogen‐based precision therapeutic applications tailored to ischemia‐reperfusion injury.


  • Open Access

    Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats

    by Chaoqun Nie, Rentong Zou, Shuang Pan, Rong A, Yunan Gao, Hongxiao Yang, Juncai Bai, Shuiqing Xi, Xue Wang, Xiaojian Hong, et al.

    It is noteworthy that prolonged cardiac structural changes and excessive fibrosis caused by myocardial infarction (MI) seriously interfere with the treatment of heart failure in clinical practice. Currently, there are no effective and practical means of either prevention or treatment. Thus, novel therapeutic approaches are critical for the long‐term quality of life of individuals with myocardial ischaemia. Herein, we aimed to explore the protective effect of H2, a novel gas signal molecule with anti‐oxidative stress and anti‐inflammatory effects, on cardiac remodelling and fibrosis in MI rats, and to explore its possible mechanism. First, we successfully established MI model rats, which were then exposed to H2 inhalation with 2% concentration for 28 days (3 hours/day). The results showed that hydrogen gas can significantly improve cardiac function and reduce the area of cardiac fibrosis. In vitro experiments further proved that H2 can reduce the hypoxia‐induced damage to cardiomyocytes and alleviate angiotensin II‐induced migration and activation of cardiac fibroblasts. In conclusion, herein, we illustrated for the first time that inhalation of H2 ameliorates myocardial infarction‐induced cardiac remodelling and fibrosis in MI rats and exert its protective effect mainly through inhibiting NLRP3‐mediated pyroptosis.